The drug maker s consolidated net profit soared 170% to Rs 297 crore on 68% surge in net sales to Rs 1,412 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, EBITDA grew 147% to Rs 477 crore in Q4 FY21 over Q4 FY20 while EBITDA margins stood at 34%. The board approved an interim dividend amounting to Re 0.80 per share.
The net profit soared 286% to Rs 984 crore on 70% surge in net sales to Rs 4,814 crore in the year ended March 2021 (FY21) over the year ended March 2020 (FY20). EBITDA grew 176% to Rs 1,573 crore in FY21 over FY20 while EBITDA margins stood at 33%.
The Reaseach and Development (R&D) expense stood at Rs 184 crore in FY21 which is 4% of its sales in FY21. The Generic FDF segment recorded a sale of Rs 430 crore, which is 30% of the contribution in Q4 and Rs 1,664 crore, 35% contribution in FY21.
Laurus Labs’ Q4 net at ₹297 crore
April 29, 2021
Its total revenue increased 68% at ₹1,412 crore
Laurus Labs Ltd’s consolidated net profit more than doubled at ₹297 crore in the fourth quarter ended March 31, 2021 compared to ₹110 crore in the corresponding quarter of the previous fiscal. The total revenue increased 68 per cent at ₹1,412 crore.
For the full year, the net profit increased 286 per cent to ₹984 crore on a revenue of ₹4,814 crore which registered 68 per cent increase over previous financial year.
“We delivered a strong performance in all divisions, and we are very confident in strengthening on it further in FY 2022 and beyond. I am extremely happy to share that we have registered a sales increase of ₹1,981 crores in a single financial year,” Satyanarayana Chava – Founder & CEO, Laurus, said in a release issued here on Thursday.
Laurus Labs Ltd posts Q4FY21 consolidated PAT higher at Rs 296 68 crores equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.